Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:G16B* AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/198865OLIGOPEPTIDES FOR QUANTITATIVE VIRAL PROTEOMIC ANALYSIS METHODS AND USES
WO 08.10.2020
Int.Class C07K 14/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
18Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
Appl.No PCT/CA2020/050431 Applicant THE UNIVERSITY OF BRITISH COLUMBIA Inventor JEAN, François
Provided are purified oligopeptides, labelled oligopeptides, and stable isotope labelled oligopeptides, methods for their use in determining the maturation status of the flaviruses or coronaviruses in a human biological sample. The purified oligopeptides, labelled oligopeptides, and stable isotope labelled oligopeptides may also be used to measure the level of the flavirus protein or coronavirus protein in a human biological sample. Methods are also provided for treating a subject based on the maturation status of the flaviruses or the coronaviruses in the subject's biological sample and/or based on the level of the flavirus or coronavirus protein in the subject's biological sample.
2.111334868Construction method of novel coronavirus whole-genome high-throughput sequencing library, and kit for library construction
CN 26.06.2020
Int.Class C40B 50/08
CCHEMISTRY; METALLURGY
40COMBINATORIAL TECHNOLOGY
BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES
50Methods of creating libraries, e.g. combinatorial synthesis
08Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creation; Particular methods of cleavage from the liquid support
Appl.No 202010225821.0 Applicant FUZHOU FURUI MEDICAL INSPECTION LABORATORY CO., LTD. Inventor WANG YANG
The invention provides a construction method of a novel coronavirus whole-genome high-throughput sequencing library, and a kit for library construction. The method comprises the following steps: 1) carrying out reverse transcription on virus RNA; (2) carrying out a first round of PCR reaction by utilizing multiple amplification primers of an anchoring part Illumina linker sequence; and 3) carryingout a second round of PCR reaction by using a labeled Illumina library amplification primer, and purifying the amplification product to obtain the high-throughput sequencing library. The anchoring multiplex amplification primer combination provided by the invention is utilized, so the efficient targeted enrichment can be performed on the genome of the novel coronavirus COVID-19, the influence that an existing method is low in targeting, low in experimental timeliness and prone to being brought into host background pollution is overcome, COVID-19 virus whole genome sequencing can be completedwithin a short time with the small sequencing data volume and cost, so differential diagnosis and virus mutation identification of the COVID-19 virus are achieved.
3.111081316Method and device for screening candidate drugs for COVID-19
CN 28.04.2020
Int.Class G16B 20/30
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
20ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
30Detection of binding sites or motifs
Appl.No 202010216192.5 Applicant GENEIS TECHNOLOGY (BEIJING) CO., LTD. Inventor PENG LIHONG
The invention discloses a method and device for screening COVID-19 drugs. On the basis of obtaining sequence similarity information between viruses and structure similarity information between pharmaceutical chemical structures, a heterogeneous network based on virus sequence similarity and drug similarity is constructed, and training is performed on the constructed data set by using a random walkalgorithm so as to obtain a COVID-19 drug screening model. Based on the drug screening model, drugs related to new coronal pneumonia can be effectively screened. According to the method, the researchand development cost of the COVID-19 drugs can be reduced, and the screening speed and accuracy of the COVID-19 drugs exceed those of representative methods applied to other bioinformatics fields.
4.111445955Novel coronavirus variation analysis method and application
CN 24.07.2020
Int.Class G16B 30/10
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
30ICT specially adapted for sequence analysis involving nucleotides or amino acids
10Sequence alignment; Homology search
Appl.No 202010280808.5 Applicant GUANGZHOU VISION GENE TECHNOLOGY CO., LTD. Inventor XU TENG
The invention relates to a novel coronavirus variation analysis method and application, and belongs to the technical field of gene sequencing analysis. The method comprises the steps of data acquisition, data filtering, data comparison, variation detection, coordinate analysis, coordinate correction and variation annotation. According to the method, variation detection can be carried out on pure virus culture sequencing data, variation detection can also be carried out on metagenome sequencing data, and the application range is wider; and meanwhile, ribosome transcoding can be accurately annotated, and joint mutation can be accurately annotated, so that the mutation detection accuracy is improved; and in addition, the virus variation can be dynamically monitored.
5.111462821Pathogenic microorganism analysis and identification system and application thereof
CN 28.07.2020
Int.Class G16B 30/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
30ICT specially adapted for sequence analysis involving nucleotides or amino acids
Appl.No 202010281509.3 Applicant GUANGZHOU VISION GENE TECHNOLOGY CO., LTD. Inventor XU TENG
The invention relates to a pathogenic microorganism analysis and identification system and application thereof, and belongs to the technical field of gene detection and analysis. The pathogenic microorganism analysis and identification system comprises: a data acquisition module used for acquiring gene sequencing data obtained by high-throughput sequencing; a data filtering module used for performing low-quality sequence filtering and host sequence filtering in sequence; a data comparison module used for comparing sequences to a pathogenic microorganism genome database; a species comparison module used for counting to-be-analyzed sequences; a data analysis module used for calculating the similarity S and the average similarity value SMSi of each species on each sequence comparison in the common comparison sequence set; a species sequence module used for calculating the total comparison sequence number SNTi of the species; and a result output module used for carrying out bioinformaticsanalysis to obtain a pathogenic microorganism analysis and identification result. The pathogenic microorganism analysis and identification system has the advantages of short analysis time and high accuracy, and can accurately detect mixed infection and obtain specific pathogen information.
6.111809246一种筛选小分子拟肽类抑制剂的方法及其应用
CN 23.10.2020
Int.Class C40B 30/04
CCHEMISTRY; METALLURGY
40COMBINATORIAL TECHNOLOGY
BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES
30Methods of screening libraries
04by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
Appl.No 202010715274.4 Applicant 金华职业技术学院 Inventor 毛辉
本发明公开了一种基于COVID‑19RdRp变构位点筛选小分子拟肽类抑制剂的方法及其应用。其中筛选方法具体包括:1)SARS‑Cov‑2‑RdRp蛋白晶体结构的处理;2)确定药物结合位点;3)化合物库的选择;4)化合物结构处理;5)分子对接;6)结果与分析。本发明充分发挥了虚拟筛选的优势,减少了实验的盲目性,有效提高了抑制剂药物的成功率,节省了人力、物力和财力。本发明还提供了筛选获得的抑制剂在制备治疗新型冠状病毒药物中的应用。
7.20180265935Virome capture sequencing platform, methods of designing and constructing and methods of using
US 20.09.2018
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
Appl.No 15759937 Applicant The Trustees of Columbia University in the City of New York Inventor Walter Ian Lipkin

The present invention provides novel methods, systems, tools, and kits for the simultaneous detection, identification and/or characterization of all viruses known or suspected to infect vertebrates. The methods, systems, tools, and kits described herein are based upon the virome capture sequencing platform (“VirCapSeq-VERT”), a novel platform developed by the inventors. The invention also provides methods and kits for designing and constructing of the virome capture sequencing platform.

8.111354420Research and development method of siRNA for COVID-19 virus drug therapy
CN 30.06.2020
Int.Class G16B 40/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
40ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Appl.No 202010154526.0 Applicant JILIN UNIVERSITY Inventor ZHU XIAODONG
The invention discloses a research and development method of siRNA for COVID-19 virus drug therapy, which comprises: a first part of preliminarily screening potential high-efficiency siRNA based on multiple indexes, which specifically comprises the following steps: step 1, selecting an S gene sequence as a target sequence; step 2, obtaining a corresponding siRNA double strand; step 3, screening asiRNA sequence with a concentration of 36 to 53%; step 4, screening out siRNA with free energy; step 5, defining and calculating an index I; step 6, screening out siRNA of the first 50%; step 7, defining and calculating an index II; step 8, screening out siRNA with the index II being equal to 5; step 9, defining and calculating an index III; step 10, ranking the first 50% of siRNA; step 11, directly taking all the candidate siRNAs selected in the step 10; step 12, specifically targeting a target sequence; step 13, taking the remaining siRNA as the siRNA subjected to preliminary screening; anda second part of performing interference efficiency prediction and optimization by using a machine learning model. The method has the beneficial effect of realizing safe, reliable and high-interference-efficiency siRNA design.
9.111785328基于门控循环单元神经网络的冠状病毒序列识别方法
CN 16.10.2020
Int.Class G16B 30/10
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
30ICT specially adapted for sequence analysis involving nucleotides or amino acids
10Sequence alignment; Homology search
Appl.No 202010537286.2 Applicant 中国人民解放军军事科学院军事医学研究院 Inventor 应晓敏
本发明涉及基于门控循环单元神经网络的冠状病毒序列识别方法,其包括如下步骤:S1:进行数据收集;S2:对所收集的数据进行预处理,从原始训练样本中进行数据抽取得到训练集、验证集和测试集;建立基于冠状病毒序列的独立测试集;S3:对S2中获得各数据集进行编码,建立训练冠状病毒序列的分类模型;S4:对该模型进行修正;S5:统计该模型对将冠状病毒序列与人的基因组序列合并以后的测试集的每条序列的输出分值;S6:并根据该输出分值的分布情况设置拒识区间,以便减少误差;S7:当输出分值≥拒识区间的上限阈值时,判断序列为冠状病毒序列;当输出分值≤拒识区间的下限阈值时,判断序列为人基因组序列。
10.20190180846SYSTEM AND METHOD FOR ANALYSIS OF BIOLOGICAL DATA
US 13.06.2019
Int.Class G16B 40/20
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
40ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
20Supervised data analysis
Appl.No 16324562 Applicant MeMed Diagnostics Ltd. Inventor Kfir OVED

A method of analyzing biological data is disclosed. The method comprises obtaining biological data containing at least an expression level of MX dynamin-like GTPase 1 (MX1) and an expression level of C-reactive protein (CRP) in the blood of a subject, calculating a distance between a segment of a curved line and an axis defined by a direction, the distance being calculated at a point over the curved line defined by a coordinate along the direction, and correlating the distance to the presence of, absence of, or likelihood that the subject has, a bacterial infection.